Charles Schwab Investment Management Inc. Has $16.20 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Charles Schwab Investment Management Inc. raised its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 24.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 899,175 shares of the company’s stock after buying an additional 177,836 shares during the period. Charles Schwab Investment Management Inc. owned about 0.08% of Teva Pharmaceutical Industries worth $16,203,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Sequoia Financial Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 0.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after purchasing an additional 805 shares during the last quarter. Smithfield Trust Co lifted its stake in shares of Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares during the last quarter. Signaturefd LLC lifted its stake in shares of Teva Pharmaceutical Industries by 16.9% in the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after purchasing an additional 1,094 shares during the last quarter. QRG Capital Management Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 0.8% in the 2nd quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock valued at $2,355,000 after purchasing an additional 1,191 shares during the last quarter. Finally, United Services Automobile Association lifted its stake in shares of Teva Pharmaceutical Industries by 3.1% in the 2nd quarter. United Services Automobile Association now owns 41,159 shares of the company’s stock valued at $669,000 after purchasing an additional 1,249 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.55% of the company’s stock.

Analyst Ratings Changes

TEVA has been the subject of several analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $17.33 on Friday. The firm has a market cap of $19.63 billion, a PE ratio of -20.39, a price-to-earnings-growth ratio of 1.06 and a beta of 0.79. Teva Pharmaceutical Industries Limited has a 12 month low of $9.35 and a 12 month high of $19.31. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The company’s 50-day moving average price is $17.54 and its two-hundred day moving average price is $17.38.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.